European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Leaders from across the NHS, government, industry and academia have called for a fundamental shift in how artificial intelligence is adopted across the health service, arguing that the NHS must move beyond isolated pilots and create clearer, faster routes to…
Health Innovation Kent Surrey Sussex (KSS) and Doctors Training have co-designed and co-delivered Generative AI (GenAI) training for NHS clinical staff, ensuring ethical, scalable, and high-quality workforce education.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us